NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (<a>NASDAQ: RARE</a>). Such investors are advised to contact Danielle Peyton at <a><u>[email protected]</u></a> or 646-581-9980, ext. 7980. \n\nThe investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. \n\nOn July 9, 2025, Ultragenyx and its development partner Mereo BioPharma Group plc issued a press release “announc[ing] that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]” Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur “around the end of the year.” \n\nOn this news, Ultragenyx’s stock price fell $10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025.\n\nThe Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See <a><u>www.pomerantzlaw.com</u></a>.\n\nAttorney advertising. Prior results do not guarantee similar outcomes. \n\nCONTACT:Danielle PeytonPomerantz LLP<a>[email protected]</a>646-581-9980 ext. 7980

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), following a press release about clinical trial progress that caused the company's stock to drop 25.11% to $31.04 per share. The law firm, based in New York, Chicago, Los Angeles, London, and Paris, specializes in securities class actions and corporate litigation.